Ta strona używa pliki cookies, w celu polepszenia użyteczności i funkcjonalności oraz w celach statystycznych. Dowiedz się więcej w Polityce prywatności.
Korzystając ze strony wyrażasz zgodę na używanie plików cookies, zgodnie z aktualnymi ustawieniami przeglądarki.
Akceptuję wykorzystanie plików cookies
Contemporary Oncology
eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Research Gate
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
2/2025
vol. 29
 
Share:
Send email
Share:
Original paper

Preoperative systemic inflammatory biomarkers can improve recurrence prediction of non-muscle invasive bladder cancer after endoscopic resection – a prospective observational study

Klaudia Bardowska
1
,
Wojciech Krajewski
2
,
Anna Kołodziej
2
,
Katarzyna Kościelska-Kasprzak
3
,
Dorota Bartoszek
3
,
Marcelina Żabińska
3
,
Joanna Chorbińska
2
,
Tomasz Królicki
4
,
Magdalena Krajewska
5
,
Tomasz Szydełko
2
,
Dorota Kamińska
5

  1. Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wrocław, Poland
  2. University Centre of Excellence in Urology, Wroclaw Medical University, Wrocław, Poland
  3. Department of Preclinical Sciences, Pharmacology and Medical Diagnostics, Faculty of Medicine, Wroclaw University of Science and Technology, Wrocław, Poland
  4. Department of Anesthesiology and Intensive Care, Institute of Medical Sciences, University of Opole, Opole, Poland
  5. Department of Non-Procedural Clinical Sciences, Faculty of Medicine, University of Science and Technology, Wrocław, Poland
Contemp Oncol (Pozn) 2025; 29 (2): 188–194
DOI: https://doi.org/10.5114/wo.2025.151064
Online publish date: 2025/05/13
Article file
- Preoperative systemic (1).pdf  [0.14 MB]
Get citation
 
PlumX metrics:
 
1. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet (London, England) 2009; 374: 239-249.
2. Didkowska JA, Wojciechowska U, Barańska K, Miklewska M, Michałek I, Olasek P. Cancer in Poland in 2021. Krajowy Rejestr Nowotworów.
3. Jubber I, Ong S, Bukavina L, et al. Epidemiology of bladder cancer in 2023: a systematic review of risk factors. Eur Urol 2023; 84: 176-190.
4. Grabe-Heyne K, Henne C, Mariappan P, Geiges G, Pöhlmann J, Pollock RF. Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Front Oncol 2023; 13: 1170124.
5. Lopez-Beltran A, Cookson MS, Guercio BJ, Cheng L. Advances in diagnosis and treatment of bladder cancer. BMJ 2024; 384: e076743.
6. Yanagisawa T, Quhal F, Kawada T, et al. Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer: a meta-analysis. BJU Int 2023; 131: 643-659.
7. Non-muscle-invasive bladder cancer. Disease management. EAU Guidelines. Available from: https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer (accessed: 28.07.2024).
8. Maas M, Bedke J, Stenzl A, Todenhöfer T. Can urinary biomarkers replace cystoscopy? World J Urol 2019; 37: 1741-1749.
9. López-Cortés R, Gómez BB, Vázquez-Estévez S, Pérez-Fentes D, Núñez C. Blood-based protein biomarkers in bladder urothelial tumors. J Proteomics 2021; 247: 104329.
10. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 2003; 89: 1028.
11. Proctor MJ, Morrison DS, Talwar D, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 2011; 104: 726.
12. Liu K, Tang S, Liu C, et al. Systemic immune-inflammatory biomarkers (SII, NLR, PLR and LMR) linked to non-alcoholic fatty liver disease risk. Front Immunol 2024; 15: 1337241.
13. Królicki T, Bardowska K, Kościelska-Kasprzak K, Mazanowska O, Krajewska M, Kamińska D. Systemic inflammatory markers predict detrimental outcome of urosepsis in kidney transplant recipients. Transplant Proc 2020; 52: 2382-2387.
14. Ma M, Li G, Zhou B, et al. Comprehensive analysis of the association between inflammation indexes and complications in patients undergoing pancreaticoduodenectomy. Front Immunol 2023; 14: 1303283.
15. Huang H, Liu Q, Zhu L, et al. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer. Sci Rep. 2019; 9: 3284.
16. Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga- Taylor AJ. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med 2020; 18: 360.
17. Platini H, Ferdinand E, Kohar K, et al. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers for advanced non-small-cell lung cancer treated with immunotherapy: a systematic review and meta-analysis. Medicina (Kaunas) 2022; 58: 1069.
18. Nøst TH, Alcala K, Urbarova I, et al. Systemic inflammation markers and cancer incidence in the UK Biobank. Eur J Epidemiol 2021; 36: 841-848.
19. Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res 2017; 19: 2.
20. Yu Y, Wang H, Yan A, et al. Pretreatment neutrophil to lymphocyte ratio in determining the prognosis of head and neck cancer: a meta-analysis. BMC Cancer 2018; 18: 383.
21. Yin X, Xiao Y, Li F, Qi S, Yin Z, Gao J. Prognostic role of neutrophil- to-lymphocyte ratio in prostate cancer: a systematic review and meta-analysis. Medicine (Baltimore) 2016; 95: e2544.
22. Wang L, Li X, Liu M, Zhou H, Shao J. Association between monocyte- to-lymphocyte ratio and prostate cancer in the U.S. population: a population-based study. Front cell Dev Biol 2024; 12: 1372731.
23. Vartolomei MD, Porav-Hodade D, Ferro M, et al. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): a systematic review and meta-analysis. Urol Oncol Semin Orig Investig 2018; 36: 389-399.
24. Araujo DC, Rocha BA, Gomes KB, et al. Unlocking the complete blood count as a risk stratification tool for breast cancer using machine learning: a large scale retro pective study. Sci Rep 2024; 14.
25. Brown JT, Liu Y, Shabto JM, et al. Modified Glasgow prognostic score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. J Immunother cancer 2021; 9: e002851.
26. Freitas C, Jacob M, Tavares N, et al. Modified Glasgow prognostic score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents. Anticancer Drugs 2021; 32: 567-574.
27. Kakiuchi Y, Kuroda S, Choda Y, et al. Prognostic nutritional index is a prognostic factor for patients with gastric cancer and esophagogastric junction cancer undergoing proximal gastrectomy with esophagogastrostomy by te double-flap technique: a secondary analysis of the rD-FLAP study. Surg Oncol 2023; 50: 101990.
28. Mao C, Xu W, Ma W, Wang C, Guo Z, Yan J. Prognostic value of pretreatment prognostic nutritional index in patients with renal cell carcinoma: a meta-analysis. Front Oncol 2021; 11: 719941.
29. Dursun A, Ertekin SC, Tuncer GK, Karaali C, Sert I. Prognostic nutritional index in short-term postoperative outcomes in hepaticojejunostomy. J Coll Physicians Surg Pak 2022; 32: 864-868.
30. Liu CC, Liu PH, Chen HT, et al. Association of preoperative prognostic nutritional index with risk of postoperative acute kidney injury: a meta-analysis of observational studies. Nutrients 2023; 15: 2929.
31. Ushirozako H, Hasegawa T, Yamato Y, et al. Does preoperative prognostic nutrition index predict surgical site infection after spine surgery? Eur Spine J 2021; 30: 1765-1773.
32. Kimura S, D’ Andrea D, Soria F, et al. Prognostic value of modified Glasgow prognostic score in non-muscle-invasive bladder cancer. Urol Oncol 2019; 37: 179.e19-179.e28.
33. Cui J, Chen S, Bo Q, et al. Preoperative prognostic nutritional index and nomogram predicting recurrence-free survival in patients with primary non-muscle-invasive bladder cancer without carcinoma in situ. Onco Targets Ther 2017; 10: 5541-5550.
34. Yuksel OH, Akan S, Urkmez A, Yildirim C, Sahin A, Verit A. Preoperative Glasgow prognostic score as a predictor of primary bladder cancer recurrence. Mol Clin Oncol 2016; 5: 201-206.
35. Non-muscle-invasive bladder cancer. Diagnosis. Available from: https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer (accessed: 28.07.2024).
36. Getzler I, Bahouth Z, Nativ O, Rubinstein J, Halachmi S. Preoperative neutrophil to lymphocyte ratio improves recurrence prediction of non-muscle invasive bladder cancer. BMC Urol 2018; 18: 90.
37. Aydın M, Bitkin A, Kadıhasanoğlu M, et al. Correlation of neutrophil-lymphocyte ratio and risk scores in non-muscle invasive bladder cancer. Actas Urol Esp 2019; 43: 503-508.
38. Avcı MA, Arslan B, Arslan O, Özdemir E. The role of thrombocyte/lymphocyte ratio and aspartate transaminase/alanine transaminase (de ritis) ratio in prediction of recurrence and progression in non-muscle invasive bladder cancer. Cureus 2024; 16: e59299.
Copyright: © 2025 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.